PCSK9 Inhibitors
Proprotein convertase subtilisin/Kexin type 9 (PCSK9) is an enzyme that binds to low-density lipoprotein receptors (LDL receptors), which stops LDL from being removed from the blood, leading to an increase in blood levels of LDL. The PCSK9 inhibitor blocks the PCSK9 enzyme, resulting in more LDL receptors available to remove LDL from the blood, which produces in a decrease in LDL blood levels.
&nbsp;
PCSK9 Inhibitors Epidemiology Segmentation in the 7MM
&nbsp;
<ul>
<li class="ql-align-justify">Total Prevalent Cases of Familial Hypercholesterolemia</li>
<li class="ql-align-justify">Total Diagnosed Cases of Familial Hypercholesterolemia</li>
<li class="ql-align-justify">Type-specific Cases of Familial Hypercholesterolemia</li>
<li class="ql-align-justify">Total Age Group-specific Cases of Familial Hypercholesterolemia</li>
<li class="ql-align-justify">Total Mutation-specific Cases of Familial Hypercholesterolemia</li>
<li class="ql-align-justify">Total Risk factor-specific Cases of PCSK9 Inhibitors in Prophylactic/Preventive setting</li>
<li class="ql-align-justify">Total Treated Cases of PCSK9 Inhibitors</li>
</ul>
&nbsp;
<a style="color: black;" href="https://www.delveinsight.com/report-store/pcsk9-inhibitors-pcsk9i-disease-epidemiology-forecast" target="_blank" rel="noopener noreferrer">PCSK9 Inhibitors Epidemiological Insights Observed in the 7MM</a> (2021)
The total number of incident cases of PCSK9 Inhibitors observed in the 7MM was observed to be&nbsp;3 million in the year 2021
&nbsp;
<a style="color: black;" href="https://www.delveinsight.com/report-store/pcsk9-inhibitors-market" target="_blank" rel="noopener noreferrer">PCSK9 Inhibitors Market Insight</a>
<ul>
<li class="ql-align-justify">The market size of PCSK9 Inhibitors in the 7MM was found to be approximately USD 1,309 million in 2021</li>
<li class="ql-align-justify">The market size of PCSK9 Inhibitors in the US was found to be approximately USD 729 million in 2021</li>
<li class="ql-align-justify">The market size of PCSK9 Inhibitors in the EU5 was found to be approximately USD 527 million in 2021</li>
<li class="ql-align-justify">The market size of PCSK9 Inhibitors in the Japan was found to be approximately USD 53 million in 2021</li>
</ul>
&nbsp;
PCSK9 Inhibitors Market Strengths
According to the World Heart Federation report, CVD alone, including heart disease and stroke, makes up nearly 50% of all non-communicable disease deaths. Prevention of CVD in high-risk patients by PCSK9 inhibition might help in relieving the high economic burden.
&nbsp;
PCSK9 Inhibitors Market Opportunities
Though monoclonal antibodies have, for the time being, established themselves as the most clinically useful inhibitors of PCSK9, other novel therapies are currently in various stages of development.
&nbsp;
<a style="color: black;" href="https://www.delveinsight.com/report-store/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitor-pipeline-insight" target="_blank" rel="noopener noreferrer">PCSK9 Inhibitors Emerging Drugs and Key Companies</a>
&nbsp;
<ul>
<li>AZD8233 (ION449): AstraZeneca and Ionis Pharmaceuticals</li>
<li>Cepadacursen sodium (CIVI-007): CiVi Biopharma</li>
<li>LIB003 (Lerodalcibep): LIB Therapeutics</li>
<li>MK-0616: Merck Sharp &amp;amp; Dohme</li>
</ul>

PCSK9 Inhibitors Market

PCSK9 Inhibitors Infographics

PCSK9 Inhibitors Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape